The White House issued a Section 232 proclamation on April 2, 2026 imposing a 100 percent tariff on imported patented pharmaceutical products and certain pharmaceutical ingredients, per the White House. The duty takes effect July 31, 2026 for the 17 major drug companies listed in the proclamation's Annex III, and September 29, 2026 for all other importers. Generic drugs are generally excluded.
This publication covers trade policy, not import or tax advice; importers should verify classification and dates with customs counsel before the first effective date.
What the proclamation actually builds
The tariff rests on the Section 232 national-security investigation of pharmaceutical imports opened in April 2025, which Commerce concluded found import dependence a strategic vulnerability. The structure is tiered: branded and patented drugs plus listed APIs face the full 100 percent, while Annex IV products receive a temporary zero rate. Per Crowell & Moring's analysis, companies can negotiate agreements to onshore manufacturing that reduce the applied rate to roughly 20 percent — a built-in incentive to announce US plants before the July deadline.
| Category | Rate | Effective |
|---|---|---|
| Annex III named companies (17) | 100% | July 31, 2026 |
| All other importers | 100% | September 29, 2026 |
| Annex IV listed products | 0% interim | per proclamation terms |
Related stories: The 10 Percent Global Tariff Expires July 24 Unless Congress Acts · Metals Tariff Rejig Takes Effect August 6: Who Wins, Who Pays.
Who absorbs the cost
Branded pharmaceutical imports run well above $200 billion a year, per Commerce trade data, so even partial coverage moves large numbers. Manufacturers face a choice between absorbing duty, raising US prices, or accelerating onshoring commitments; pharmacy benefit managers and health plans are already modeling formulary effects for 2027 plan years. The generic carve-out matters because generics supply roughly 90 percent of US prescriptions, per industry association data — excluding them keeps the duty aimed at brand-price margins rather than volume supply.
Why the two deadlines matter
The July 31 date applies by company name, not product: any Annex III company's covered imports bear the full rate from that day regardless of when its supply contracts renew. Smaller importers get two more months, a window for inventory buildup — imports entered before the effective dates arrive duty-free — and for agreement negotiations that could re-rate their exposure.
How it reached the president's desk
Commerce initiated the Section 232 pharmaceutical investigation on April 1, 2025 and took public comment through the Federal Register that spring, per the Federal Register notice of April 16, 2025. The statute gives the president discretion to select the remedy once Commerce reports findings; the 100 percent headline rate and company-specific annexes are that discretion at work, calibrated — per administration statements reported by trade press — to reward manufacturing commitments rather than to collect revenue.
What does this change?
The proclamation converts pharmaceutical supply-chain policy from negotiation to price signal. Companies with US manufacturing commitments can cut their rate to about 20 percent; those without face a full duty from July 31, 2026. Expect onshoring announcements to cluster before that date, and expect the tariff's legality and coverage to be litigated, as earlier Section 232 actions have been.